Many symptoms of hypertrophic cardiomyopathy (HCM) are mild, particularly in the early stages of the disease, so they may be easy to dismiss. Symptoms such as shortness of breath during exercise, ...

Good morning, and welcome to Lexeo Therapeutics webcast presentation on LX2020 for the treatment of PKP2-associated arrhythmogenic cardiomyopathy. As a reminder, this call is being recorded today, ...

Aficamten offers a new treatment option for symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Clinical trials SEQUOIA-HCM and MAPLE-HCM showed aficamten's efficacy in improving exercise ...

Myqorzo is expected to be available by the second half of January 2026. The Food and Drug Administration (FDA) has approved Myqorzo™ (aficamten) for the treatment of adults with symptomatic ...

Good afternoon, and welcome to the fireside chat titled: A Clinician's Perspective: Holistic Approach to Managing PKP2-Associated Arrhythmogenic Cardiomyopathy, hosted by Lexeo Therapeutics. As a ...

Please provide your email address to receive an email when new articles are posted on . Strength training may be as safe as sedentary behavior for people with genetic risk for ventricular arrhythmia.

Most people with HCM can participate in mild- to moderate-intensity exercise safely. When it comes to vigorous exercise and competitive sports, there may be a need for additional guidance from your ...

Please provide your email address to receive an email when new articles are posted on . Genetic risk for dilated cardiomyopathy was tied to elevated risk for secondary cardiomyopathies related to ...

Panel A shows a cross-section of a normal heart (top) and an endomyocardial biopsy sample from a normal heart (bottom; with hematoxylin and eosin staining) that shows normal histologic characteristics ...

A 67-year-old man with a history of dilated cardiomyopathy and a left ventricular ejection fraction of 40% presents to his primary care provider for a routine physical examination. His vital signs and ...